Literature DB >> 16817794

Evaluation of serological diagnosis tests for tuberculosis in hemodialysis patients.

Mitsuru Yanai1, Yuki Uehara, Makoto Takeuchi, Yuji Nagura, Tadashi Hoshino, Kuniki Hayashi, Kazunari Kumasaka.   

Abstract

Patients receiving hemodialysis are generally considered to be at increased risk of developing tuberculosis. In the current study, in order to evaluate the usefulness of serological tests in dialysis patients, serum antibodies for tuberculous glycolipids antigen (TBGL) and for lipoarabinomannan (LAM) were measured in hemodialysis patients. The present study included 243 hemodialysis patients. Serum antibodies for TBGL and LAM were measured. Tuberculin skin tests were carried out and chest X-rays evaluated at the same time. There were no patients with active tuberculosis at the time of blood sampling. Thirty-six patients (14.8%) and 25 patients (10.3%) were positive for anti-TBGL antibody and anti-LAM antibody, respectively. One hundred and fifty-five patients (63.8%) were positive for tuberculin skin testing and 123 patients (50.6%) had old pulmonary tuberculosis on their chest X-ray. There was no significant correlation between the results of anti-TBGL antibody and anti-LAM antibody. There were no relationships among the results of tuberculin skin test and the two serological tests. However, positivity of anti-TBGL antibody and anti-LAM antibody was significantly higher in patients with findings of old tuberculosis on the chest X-ray than those without findings. The current results show that these serological tests are positive more frequently in hemodialysis patients without any proof of active tuberculosis than in healthy subjects (2%) and careful interpretation is necessary for relevant results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16817794     DOI: 10.1111/j.1744-9987.2006.00381.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  2 in total

1.  High prevalence of latent tuberculosis infection in dialysis patients using the interferon-gamma release assay and tuberculin skin test.

Authors:  Susan Shin-Jung Lee; Kang-Ju Chou; Horng-Yunn Dou; Tsi-Shu Huang; Yen-Yun Ni; Hua-Chang Fang; Hung-Chin Tsai; Cheng-Len Sy; Jui-Kuang Chen; Kuang-Sheng Wu; Yung-Hsin Wang; Hsi-Hsun Lin; Yao-Shen Chen
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test.

Authors:  S S J Lee; K J Chou; I J Su; Y S Chen; H C Fang; T S Huang; H C Tsai; S R Wann; H H Lin; Y C Liu
Journal:  Infection       Date:  2008-12-10       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.